Abbisko Cayman Limited informed the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co. Ltd. announced that ABSK051, its self-developed next-generation CD73 inhibitor, has completed the first patient dose in a clinical trial. In November 2023, ABSK051 obtained the clinical trial approval from the National Medical Products Administration of the People's Republic of China to enter the first-in-human (FIH) Phase I clinical trial for the treatment of advanced solid tumors in China.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK051 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.